Genito-urinary Drugs Market Global Briefing 2017

Genito-urinary Drugs Market Global Briefing 2017

  • August 2017 •
  • 32 pages •
  • Report ID: 5057812 •
  • Format: PDF
The genitourinary drugs market covers drugs that are used in the treatment of diseases such as urinary tract infections, male reproductive diseases, voiding diseases, female reproductive diseases, glomerular disorders, urinary calculi, cystic kidney disease, Reno vascular diseases, benign prostate diseases, and other related diseases.

The global genito-urinary drugs market is expected to reach around $75 billion in 2020. This growth is mainly due to the growing genitourinary disorders like chronic kidney disease CKD and also going forward, the number of pipeline drugs (ABT-614, Abbott Laboratories and EOS789, Chugai Pharmaceutical) are expected to increase with constant improvements in healthcare infrastructure. Novel drugs such as Cialis which are considerably more effective than the drugs used in multiple-drug therapies, and are affordable in cost are expected to fuel the growth of this market.

Demand For Combination Products - The launch of combination products for the treatment of urinary tract infections is an emerging trend in the genito-urinary disorder drugs market. Competitors in the market are developing combination drugs to fight multi-drug resistant bacteria and also expanding indications for existing drugs for the treatment of genito-urinary disorders. For instance, Merck Sharp & Dohme Corp. offers ZERBAXA, a combination drug of a novel cephalosporin and a beta-lactamase inhibitor used for the treatment of complicated urinary tract infections.
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.